[go: up one dir, main page]

AR006345A1 - A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INCLUDING AN HIV PROTEASE INHIBITOR AND A WATER-SOLUBLE TOCOFEROL DERIVATIVE, AND A METHOD FOR PREPARING SUCH COMPOSITION. - Google Patents

A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INCLUDING AN HIV PROTEASE INHIBITOR AND A WATER-SOLUBLE TOCOFEROL DERIVATIVE, AND A METHOD FOR PREPARING SUCH COMPOSITION.

Info

Publication number
AR006345A1
AR006345A1 ARP970101146A ARP970101146A AR006345A1 AR 006345 A1 AR006345 A1 AR 006345A1 AR P970101146 A ARP970101146 A AR P970101146A AR P970101146 A ARP970101146 A AR P970101146A AR 006345 A1 AR006345 A1 AR 006345A1
Authority
AR
Argentina
Prior art keywords
composition
hiv protease
water
protease inhibitor
derivative
Prior art date
Application number
ARP970101146A
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR006345A1 publication Critical patent/AR006345A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a composiciones farmacéutica que contienen los inhibidores de proteasa del VIH, que incluyen específicamente el éster tetrahidro-3-furanílicodel ácido 3S-[3R*(1R*,2S*)]-3-[[(4-aminofenil)sulfonil](2-metilpropil)-amino] -2-hidroxi-]-fenilmetil)-propil]carbámico (conocido alternativamente comoVX 478 o 141W94), y un tocoferol, y a su uso en terapia médica. Las composiciones pueden ser preparadas disolviendo un inhibidor de proteasa delVIH en un derivado del tocoferolsol uble en agua.Refers to pharmaceutical compositions containing HIV protease inhibitors, specifically including 3S- [3R * (1R *, 2S *)] - 3 - [[(4-aminophenyl) sulfonyl] acid tetrahydro-3-furanyl). (2-methylpropyl) -amino] -2-hydroxy -] - phenylmethyl) -propyl] carbamic (alternatively known as VX 478 or 141W94), and a tocopherol, and its use in medical therapy. Compositions can be prepared by dissolving an HIV protease inhibitor in a tocopherol soluble derivative in water.

ARP970101146A 1996-03-22 1997-03-21 A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INCLUDING AN HIV PROTEASE INHIBITOR AND A WATER-SOLUBLE TOCOFEROL DERIVATIVE, AND A METHOD FOR PREPARING SUCH COMPOSITION. AR006345A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
AR006345A1 true AR006345A1 (en) 1999-08-25

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101146A AR006345A1 (en) 1996-03-22 1997-03-21 A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INCLUDING AN HIV PROTEASE INHIBITOR AND A WATER-SOLUBLE TOCOFEROL DERIVATIVE, AND A METHOD FOR PREPARING SUCH COMPOSITION.

Country Status (12)

Country Link
JP (1) JP3117726B2 (en)
AR (1) AR006345A1 (en)
BG (1) BG64457B1 (en)
CO (1) CO4790151A1 (en)
HU (1) HU228026B1 (en)
ID (1) ID16781A (en)
IL (1) IL126185A (en)
MY (1) MY126358A (en)
OA (1) OA10880A (en)
PL (1) PL187919B1 (en)
TW (1) TW455491B (en)
WO (1) WO1997035587A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1017366A4 (en) * 1996-09-01 2006-03-22 Pharmos Corp Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (en) * 1997-12-04 2000-10-16 Univ Granada USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
EP1354587A1 (en) * 2000-12-22 2003-10-22 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
JP2006518380A (en) 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション Solid dispersion composition
US20060068007A1 (en) * 2004-09-24 2006-03-30 Boehringer Ingelheim Pharmaceuticals, Inc. Class of surfactant-like materials
CN101031284A (en) * 2004-09-30 2007-09-05 伊斯曼化学公司 Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (en) 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
ITRM20120331A1 (en) 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1677092A (en) * 1991-03-20 1992-10-21 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
ES2112880T3 (en) * 1991-11-08 1998-04-16 Merck & Co Inc HIV PROTEASE INHIBITORS USEFUL FOR AIDS TREATMENT.
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ES2189721T3 (en) * 1992-12-29 2003-07-16 Abbott Lab RETROVIRAL PROTEASA INHIBITORS.
US5714518A (en) * 1993-01-15 1998-02-03 Agouron Pharmaceuticals HIV protease inhibitors and methods of making the same
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
CA2178760C (en) * 1993-12-15 2000-08-01 Joel R. Huff Hiv protease inhibitors
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
BG102838A (en) 1999-09-30
JP3117726B2 (en) 2000-12-18
JP2000500504A (en) 2000-01-18
HU228026B1 (en) 2012-08-28
BG64457B1 (en) 2005-03-31
PL328916A1 (en) 1999-03-01
HUP9901887A3 (en) 2000-02-28
TW455491B (en) 2001-09-21
IL126185A (en) 2003-05-29
ID16781A (en) 1997-11-13
CO4790151A1 (en) 1999-05-31
MY126358A (en) 2006-09-29
PL187919B1 (en) 2004-11-30
IL126185A0 (en) 1999-05-09
HUP9901887A2 (en) 1999-12-28
WO1997035587A1 (en) 1997-10-02
OA10880A (en) 2001-10-11

Similar Documents

Publication Publication Date Title
AR037490A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
AR006345A1 (en) A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INCLUDING AN HIV PROTEASE INHIBITOR AND A WATER-SOLUBLE TOCOFEROL DERIVATIVE, AND A METHOD FOR PREPARING SUCH COMPOSITION.
ECSP941104A (en) DERIVATIVES OF 2,6 DIAMINOPURINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
ES2233931T3 (en) PHENYLACETATE AND DERIVATIVES, ALONE OR IN COMBINATION WITH OTHER COMPOUNDS, AGAINST NEOPLASIC STATES AND OTHER DISORDERS.
ES2076935T3 (en) COMPOUND OF PIRAZOLOPYRIDINE AND PROCEDURES FOR ITS PREPARATION.
PA8575701A1 (en) ACID INSULIN PREPARATIONS WITH IMPROVED STABILITY
MX9306708A (en) FIRE FIGHTING FOAM COMPOSITIONS OF A LOW VISCOSITY POLAR SOLVENT.
AR012671A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF THE CONSTIPATION, THE USES OF SUCH COMPOSITIONS AND THE PROCESSES TO PREPARE THEM
BR0111206A (en) Arylmethylamine derivatives for use as tryptase inhibitors
ECSP034883A (en) AMIDAS OF ANTRANILIC ACIDS WITH SIDE CHAIN OF HETEROARILSULFONILO, PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT AS A MEDICINAL OR DIAGNOSTIC AGENT, AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM
AR035533A1 (en) USE OF AT LEAST AN INHIBITOR OF THE ABSORPTION OF THE STEROLS OR THEIR SALTS, SOLVATOS, PHARMACEUTICALLY ACCEPTABLE DRUGS OR MIXTURES OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF SITOSTEROLEMIA, COMPOSITIONS OF THE PHARMACEUTICAL USE
AR021922A1 (en) PHARMACEUTICAL FORMULATIONS IN AEROSOL CONTAINING FLUOROALCANS, BUDESONIDO AND FORMOTEROL.
ES2113444T3 (en) MEDICINES.
BR9714310A (en) Pharmaceutical composition
AR033688A1 (en) RECONSTITUABLE PARENTERAL COMPOSITION
AR006598A1 (en) "ANTI-FUNGOUS COMPOSITIONS, ITS USE IN THE MANUFACTURE OF MEDICINES AND A PROCEDURE FOR THE PREPARATION"
ES2192349T3 (en) ALFA-HYDROXY, AMINO AND HALO DERIVATIVES OF BETA-SULFONYL HYDROXAMIC ACIDS USED AS INHIBITORS OF MARRIAGE METALOPROTEINS.
BR0109672A (en) Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal
AR024998A1 (en) NEW RETINOIDS FOR THE TREATMENT OF THE DISEASE
ES2173883T3 (en) USE OF PIPERACINE-ACETAMIDE DERIVATIVES AGAINST REPERFUSION DAMAGES.
AR021921A1 (en) PHARMACEUTICAL FORMULATIONS IN AEROSOL CONTAINING FLUOROALCANS AND BUDESONIDO.
ES2160680T3 (en) USE OF A SUBSTANCE ANTAGONIST P IN A PHARMACEUTICAL COMPOSITION.
DK1091733T3 (en) (-) - Pseudoephedrine as a sympathomimetic drug
AR001769A1 (en) Benzamide enterokinetics pharmaceutical compositions containing them, a process for the preparation of said pharmaceutical compositions, the use of said compounds for the manufacture of medicines and a process for their preparation.
ES2091183T3 (en) METHOD TO IMPROVE SLEEP.

Legal Events

Date Code Title Description
FG Grant, registration